CRMD - CorMedix Inc.

7.57
-0.250   -3.303%

Share volume: 1,221,675
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$7.82
-0.25
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 25%
Dept financing 8%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.02%
1 Month
15.22%
3 Months
-5.61%
6 Months
-33.07%
1 Year
-17.00%
2 Year
43.37%
Key data
Stock price
$7.57
P/E Ratio 
N/A
DAY RANGE
$7.54 - $7.98
EPS 
$2.25
52 WEEK RANGE
$6.12 - $17.43
52 WEEK CHANGE
-$17.63
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
79.050 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,006,847
AVERAGE 30 VOLUME 
$1,030,521
Company detail
CEO: Joseph Todisco
Region: US
Website: cormedix.com
Employees: 30
IPO year: 2010
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CorMedix Inc. focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings.

Recent news